Clostridioides difficile infection in children hospitalised in Motol University Hospital

Czech version

Authors: Krůtová Marcela; Briksi Aleš; Dřevínek Pavel
Authors‘ workplace: Ústav lékařské mikrobiologie, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice v Motole
Published in: Čes-slov Pediat 2022; 77 (6): 340-344.
Category: Original Papers
doi: https://doi.org/10.55095/CSPediatrie2022/060

Overview

Clostridioides difficile infections (CDI) are traditionally attributed to adults, but children can also be affected. In children, when indicated, laboratory diagnosis of CDI should be combined with testing for the presence of other gastrointestinal pathogens that are a common cause of diarrhoea, particularly in younger children. This was also confirmed in a cohort of 652 children with diarrhoea admitted to the Motol University Hospital, where 71 PCR positive tests for toxigenic C. difficile revealed another infectious cause in 33.8% (n = 24) by multiplex PCR. The detection of toxigenic C. difficile by PCR does not distinguish between colonisation and active infection, so the stool sample with a positive PCR test should be tested also for the presence of toxins A/B. Of the above 71 PCR-positive stools, 65 were further tested with the immunoenzymatic assay, and simultaneous positivity of C. difficile GDH and A/B toxins was detected only in 44.6% of stools (n = 24), but in almost half of these samples (n = 10), another infectious cause of diarrhoea was detected. In recurrent CDI, as in the first episode, emphasis should be placed on combined laboratory diagnostics to exclude co-infection with another intestinal pathogen or colonization with C. difficile. Compared with adult inpatients, available clinical data in children are limited and further prospective studies are needed to determine the prevalence of CDI and the efficacy of treatment regimens.

Keywords:

fidaxomicin – Epidemiology – Vancomycin – treatment – diagnostics – ribotyping – metronidazole

Sources

1. Lawson PA , Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938. Anaerobe 2016; 40: 95–9.

2. Oren A, Rupnik M. Clostridium difficile and Clostridioides difficile: two validly published and correct names. Anaerobe 2018; 52: 125–126.

3. Paredes-Sabja D, Shen A, Sorg JA. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol 2014; 22(7): 406–16.

4. Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting Clostridium difficile recurrence. Clin Microbiol Infect 2018; 24(5): 476–82.

5. Miranda-Katz M, Parmar D, Dang R, et al. Epidemiology and risk factors for community associated Clostridioides difficile in children. J Pediatr 2020; 221: 99–106.

6. Clemente JC, Ursell LK, Parfrey LW, et al. The impact of the gut microbiota on human health: an integrative view. Cell. 2012; 148(6): 1258–70.

7. Dominguez SR, Dolan SA, West K, et al. High colonization rate and prolonged shedding of Clostridium difficile in pediatric oncology patients. Clin Infect Dis 2014; 59(3): 401–3.

8. Barbar R, Hayden R, Sun Y, et al. Epidemiologic and clinical characteristics of Clostridioides difficile infections in hospitalized and outpatient pediatric oncology and hematopoietic stem cell transplant patients. Pediatr Infect Dis J 2021; 40(7): 655–62.

9. Breuer C, Döring S, Rohde H, et al. Clostridium difficile infection after pediatric solid organ transplantation: a practical single-center experience. Pediatr Nephrol 2019; 34(7): 1269–75.

10. Mayer EF, Maron G, Dallas RH, et al. A multicenter study to define the epidemiology and outcomes of Clostridioides difficile infection in pediatric hematopoietic cell and solid organ transplant recipients. Am J Transplant 2020; 20(8): 2133–42.

11. Crobach MJ, Planche T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016; 22 Suppl 4: S63–81.

12. de Graaf H, Pai S, Burns DA, et al. Co-infection as a confounder for the role of Clostridium difficile infection in children with diarrhoea: a summary of the literature. Eur J Clin Microbiol Infect Dis 2015; 34(7): 1281–7.

13. Schutze GE, Willoughby RE; Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics 2013; 131(1): 196–200.

14. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66(7): 987–94.

15. Krutova M, de Meij TGJ, Fitzpatrick F, et al. How to: Clostridioides difficile infection in children. Clin Microbiol Infect 2022; 28(8): 1085–1090.

16. Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013; 56(10): 1401–6.

17. Wendt JM, Cohen JA, Mu Y, et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 2014; 133(4): 651–8.

18. Davies KA, Ashwin H, Longshaw CM, et al. Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. Euro Surveill 2016; 21(29).

19. Krutova M, Capek V, Nycova E, et al. The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients. Antimicrob Resist Infect Control 2020; 9(1): 98.

20. van Dorp SM, Smajlović E, Knetsch CW, et al. Clinical and microbiological characteristics of Clostridium difficile infection among hospitalized children in the Netherlands. Clin Infect Dis 2017; 64(2): 192–8.

21. Stoesser N, Eyre DW, Quan TP, et al. Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains. PLoS One 2017; 12(8): e0182307.

22. van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27(Suppl 2): S1–S21.

23. Briksí A, Hubáček P, Šumová J, et al. Porovnání tradiční a komerční molekulárně- biologické detekce gastrointestinálních patogenů firmy AusDiagnostics ve FN Motol. Klin Mikrobiol Infekc Lek 2019; 25(4): 132–139.

24. Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; European Society for Pediatric Infectious Diseases. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59(1): 132–52.

25. Krutova M, Wilcox M, Kuijper JE. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view? Int J Infect Dis 2022: S1201- 9712(22)00512-4.

26. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014. 59(3): 345–54.

27. Wolf J, Kalocsai K, Fortuny C, et al. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). Clin Infect Dis 2020; 71(10): 2581–8.

28. O ’Gorman MA, Michaels MG, Kaplan SL, et al. Safety and pharmacokinetic study of fidaxomicin in children with Clostridium difficile-associated diarrhea: a phase 2a multicenter clinical trial. J Pediatric Infect Dis Soc 2018; 7(3): 210–8.

29. European Medicines Agency, Dificlir European public assessment report, last update (04/06/2021). Available at: https: //www.ema.europa.eu/en/documents/ product-information/dificlir-epar-product-information_en.pdf

30. US Food and Drug Administration (FDA), DIFICID® (fidaxomicin), 2020. https: //www.accessdata.fda.gov/drugsatfda_docs/label/2020/213138lbl. pdf

31. Davidovics ZH, Michail S, Nicholson MR, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection and other conditions in children: a joint position paper from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2019; 68(1): 130–43.

32. Nicholson MR, Mitchell PD, Alexander E, et al. Efficacy of fecal microbiota transplantation for Clostridium difficile infection in children. Clin Gastroenterol Hepatol 2020; 18(3): 612–19.e1.